The rationale for targeting ATR is that cancer cells are under RepStress, and that their survival require active replication checkpoints, namely ATR, CHK1, and WEE1, especially when the RepStress is exacerbated by DNA-targeted agents [7] (see Section 3 and Table 1). This evidence concerns the gene ATR and cancer.